OTI Pioneer in Big Data for IP Innovation
OTI Patent Update
May 1st 2025. OTI (Massachusetts) announces its 2nd PCT publication: WO2025090106 - COMPOSITIONS AND METHODS FOR TREATING NEURAL DEGENERATION IN GLAUCOMA AND RELATED CONDITIONS. This patent protects the breakthrough discovery of glaucoma disease root cause and matrix metalloproteinase (MMP) platform therapy for treating glaucoma neural degeneration via IOP normalization (new). OTI is creating a new MMP therapeutic market for glaucoma specialty care.
March 10, 2025. OTI (Massachusetts) announces the completion of the first PCT national phase filings with US, EU, Canada, Australia, Japan, China, and India. PCT #1 Pub Number: WO2024030766 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED CONDITIONS.